Paul J Neeson

List of Publications by Year
in descending order

Version: 2024-02-01

101 papers	4,679 citations	147566 31 h-index	110170 64 g-index
101 all docs	101 docs citations	101 times ranked	7702 citing authors

#	Article	IF	Citations
1	Basic cancer immunology for radiation oncologists. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 508-518.	0.9	2
2	Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation. , 2022, 10, e004095.		7
3	Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment. , 2022, 10, e004574.		6
4	Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy. European Urology Focus, 2021, 7, 234-237.	1.6	31
5	Multiplex Immunohistochemistry Analysis of Melanoma Tumor-Infiltrating Lymphocytes. Methods in Molecular Biology, 2021, 2265, 557-572.	0.4	10
6	Chimeric Antigen Receptor beyond CAR-T Cells. Cancers, 2021, 13, 404.	1.7	29
7	Generating CAR T cells from tumor-infiltrating lymphocytes. , 2021, 9, 251513552110171.	1.4	6
8	Study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 radionuclide therapy prior to radical prostatectomy in men with high-risk localized prostate cancer (LuTectomy study).. Journal of Clinical Oncology, 2021, 39, TPS264-TPS264.	0.8	1
9	Î³Î´ T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival. Cancer Immunology Research, 2021, 9, 612-623.	1.6	22
10	Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs. Frontiers in Immunology, 2021, 12, 632399.	2.2	30
11	CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nature Communications, 2021, 12, 3236.	5.8	99
12	Myeloma natural killer cells are exhausted and have impaired regulation of activation. Haematologica, 2021, 106, 2522-2526.	1.7	8
13	CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory. Cancer Discovery, 2021, 11, 2582-2601.	7.7	62
14	A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 2766-2778.	1.3	9
15	Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nature Immunology, 2021, 22, 851-864.	7.0	97
16	Transcriptome sequencing and multi-plex imaging of prostate cancer microenvironment reveals a dominant role for monocytic cells in progression. BMC Cancer, 2021, 21, 846.	1.1	3
17	Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II). JAMA Oncology, 2021, 7, 1476.	3.4	50
18	MAIT cells regulate NK cell-mediated tumor immunity. Nature Communications, 2021, 12, 4746.	5.8	45

#	Article	IF	Citations
19	Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma. Cancers, 2021, 13, 4704.	1.7	9
20	Regulatory T Cells Shape the Differential Impact of Radiation Dose-Fractionation Schedules on Host Innate and Adaptive Antitumor Immune Defenses. International Journal of Radiation Oncology Biology Physics, 2021, 111, 502-514.	0.4	22
21	Single-Cell Gene Expression, Clonality, and Feature Barcoding of Melanoma Tumor-Infiltrating Lymphocytes. Methods in Molecular Biology, 2021, 2265, 529-541.	0.4	1
22	Using Mass Cytometry to Analyze the Tumor-Infiltrating Lymphocytes in Human Melanoma. Methods in Molecular Biology, 2021, 2265, 543-555.	0.4	1
23	Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment. Cancer Immunology, Immunotherapy, 2021, 70, 1811-1820.	2.0	11
24	PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia. Haematologica, 2021, 106, 3115-3124.	1.7	17
25	Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES). , 2021, 9, e002995.		18
26	Enhancing the Potential of Immunotherapy in Paediatric Sarcomas: Breaking the Immunosuppressive Barrier with Receptor Tyrosine Kinase Inhibitors. Biomedicines, 2021, 9, 1798.	1.4	6
27	CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors. Frontiers in Immunology, 2021, 12, 813832.	2.2	15
28	Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma. Haematologica, 2020, 105, e76-e79.	1.7	37
29	A Distinct Pretreatment Immune Gene Signature in Lentigo Maligna Is Associated with Imiquimod Response. Journal of Investigative Dermatology, 2020, 140, 869-877.e16.	0.3	15
30	Validation and characterisation of prognostically significant PD-L1+ immune cells in HPV+ oropharyngeal squamous cell carcinoma. Oral Oncology, 2020, 101, 104516.	0.8	17
31	IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors. Molecular Therapy, 2020, 28, 2379-2393.	3.7	49
32	Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report. BMC Urology, 2020, 20, 171.	0.6	7
33	Therapeutic strategies to remodel immunologically cold tumors. Clinical and Translational Immunology, 2020, 9, e1226.	1.7	23
34	Highâ€dimensional analyses reveal a distinct role of Tâ€cell subsets in the immune microenvironment of gastric cancer. Clinical and Translational Immunology, 2020, 9, e1127.	1.7	21
35	P53: A Guardian of Immunity Becomes Its Saboteur through Mutation. International Journal of Molecular Sciences, 2020, 21, 3452.	1.8	56
36	TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival. Cancers, 2020, 12, 1535.	1.7	30

#	Article	IF	Citations
37	High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. , 2020, 8, e000792.		45
38	Immune profiling of pediatric solid tumors. Journal of Clinical Investigation, 2020, 130, 3391-3402.	3.9	27
39	Challenges of PD-L1 testing in non-small cell lung cancer and beyond. Journal of Thoracic Disease, 2020, 12, 4541-4548.	0.6	13
40	Accumulation of CD103⁺ CD8⁺ T cells in a cutaneous melanoma micrometastasis. Clinical and Translational Immunology, 2019, 8, e1100.	1.7	8
41	Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy. Blood, 2019, 134, 4290-4290.	0.6	0
42	Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma. Scientific Reports, 2018, 8, 4159.	1.6	79
43	Human blood MAIT cell subsets defined using MR1 tetramers. Immunology and Cell Biology, 2018, 96, 507-525.	1.0	205
44	Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2068-E2076.	3.3	224
45	Exploring the oncoproteomic response of human prostate cancer to therapeutic radiation using dataâ€independent acquisition (DIA) mass spectrometry. Prostate, 2018, 78, 563-575.	1.2	23
46	The Transcriptional Landscape of Radiation-Treated Human Prostate Cancer: Analysis of a Prospective Tissue Cohort. International Journal of Radiation Oncology Biology Physics, 2018, 100, 188-198.	0.4	24
47	IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma. Expert Opinion on Investigational Drugs, 2018, 27, 691-697.	1.9	12
48	High mammographic density in women is associated with protumor inflammation. Breast Cancer Research, 2018, 20, 92.	2.2	26
49	Biodosimetric transcriptional and proteomic changes are conserved in irradiated human tissue. Radiation and Environmental Biophysics, 2018, 57, 241-249.	0.6	8
50	A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. Cancer Research, 2017, 77, 1296-1309.	0.4	61
51	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. Clinical Cancer Research, 2017, 23, 2478-2490.	3.2	95
52	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. Nature Communications, 2017, 8, 606.	5.8	89
53	CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature, 2017, 549, 101-105.	13.7	624
54	Immunological battlefield in gastric cancer and role of immunotherapies. World Journal of Gastroenterology, 2016, 22, 6373.	1.4	33

#	Article	IF	Citations
55	Allogeneic CAR19 cells clear ALL. Blood, 2016, 127, 1224-1225.	0.6	1
56	Diversity of T Cells Restricted by the MHC Class I-Related Molecule MR1 Facilitates Differential Antigen Recognition. Immunity, 2016, 44, 32-45.	6.6	169
57	Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. Seminars in Immunology, 2016, 28, 64-72.	2.7	52
58	Bigger, Stronger, Faster: Chimeric Antigen Receptor T Cells Are Olympic Killers. Blood, 2016, 128, 814-814.	0.6	2
59	Myelosuppressive Therapies Significantly Increase Pro-Inflammatory Cytokines and Directly Cause Bone Loss. Journal of Bone and Mineral Research, 2015, 30, 886-897.	3.1	35
60	CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells. Cancer Immunology Research, 2015, 3, 483-494.	1.6	103
61	Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression. Immunotherapy, 2015, 7, 499-512.	1.0	18
62	Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib. OncoImmunology, 2015, 4, e1038011.	2.1	4
63	Adoptive immunotherapy: a new era for the treatment of cancer. Immunotherapy, 2015, 7, 469-471.	1.0	4
64	CAR-T cells are serial killers. OncoImmunology, 2015, 4, e1053684.	2.1	14
65	A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in Mice. Biology of Blood and Marrow Transplantation, 2015, 21, 242-249.	2.0	3
66	Targeting Mechanisms for Natural Killer Cell Dysfunction in Patients with Multiple Myeloma. Blood, 2015, 126, 4237-4237.	0.6	2
67	CAR-T Cells Are Serial Killers of Tumor Cells. Blood, 2015, 126, 3088-3088.	0.6	0
68	Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. Leukemia and Lymphoma, 2014, 55, 1053-1060.	0.6	12
69	Manipulating immune cells for adoptive immunotherapy of cancer. Current Opinion in Immunology, 2014, 27, 46-52.	2.4	46
70	B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21. International Immunology, 2014, 26, 383-395.	1.8	13
71	The Drug Vehicle and Solvent N-Methylpyrrolidone Is an Immunomodulator and Antimyeloma Compound. Cell Reports, 2014, 7, 1009-1019.	2.9	34
72	OMIPâ€021: Simultaneous quantification of human conventional and innateâ€like Tâ€cell subsets. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2014, 85, 573-575.	1.1	7

#	Article	IF	Citations
73	Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor. Immunotherapy, 2013, 5, 577-590.	1.0	5
74	Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia. Molecular Therapy, 2013, 21, 2122-2129.	3.7	361
75	Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy. Clinical and Experimental Immunology, 2013, 175, 49-58.	1.1	35
76	CD57+ NK CELLS ARE Increased In Patients With Multiple Myeloma and ARE Primed Effectors For ADCC, But NOT Natural Cytotoxicty. Blood, 2013, 122, 1904-1904.	0.6	8
77	Novel Predictor Of Lenalidomide Response In Non-del5q MDS Reveals Linkage To Molecular Mechanism: First Characterization Of T-Cell Function In Cereblon Homozygous Deficient Mice. Blood, 2013, 122, 748-748.	0.6	1
78	Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?. OncoImmunology, 2012, 1, 372-374.	2.1	13
79	A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood, 2011, 118, 6274-6283.	0.6	83
80	The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood, 2011, 117, 1605-1613.	0.6	152
81	Response: dexamethasone dose alters expression of NK activating receptors in vivo. Blood, 2011, 118, 6466-6468.	0.6	4
82	Drug-mediated and cellular immunotherapy in multiple myeloma. Immunotherapy, 2010, 2, 243-255.	1.0	13
83	Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Therapy, 2010, 17, 678-686.	2.3	105
84	Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. Gene Therapy, 2010, 17, 1105-1116.	2.3	38
85	Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia, 2010, 24, 22-32.	3.3	505
86	Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients. Leukemia, 2010, 24, 592-600.	3.3	36
87	Tumor Ablation by Gene-Modified T Cells in the Absence of Autoimmunity. Cancer Research, 2010, 70, 9591-9598.	0.4	49
88	The level of glycolytic metabolism in acute myeloid leukemia blasts at diagnosis is prognostic for clinical outcome. Journal of Leukocyte Biology, 2010, 89, 51-55.	1.5	90
89	The anti-cancer drug, phenoxodiol, kills primary myeloid and lymphoid leukemic blasts and rapidly proliferating T cells. Haematologica, 2009, 94, 928-934.	1.7	21
90	Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma. Cancer Immunology, Immunotherapy, 2008, 57, 493-505.	2.0	25

#	Article	IF	Citations
91	Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice. Gene Therapy, 2008, 15, 1056-1066.	2.3	25
92	Regulatory T Cells (Treg) Are Depressed in Patients with Relapsed/Refractory Multiple Myeloma (MM) and Increases towards Normal Range in Responding Patients Treated with Lenalidomide (LEN).. Blood, 2008, 112, 1696-1696.	0.6	19
93	The Level of Glycolytic Metabolism of AML Blasts May Predict Drug Sensitivity and Prognosis in Patients with AML. Blood, 2008, 112, 4022-4022.	0.6	0
94	Gene-Modified CD8+ T Cells Undergo Functional Polarization to Effector and Central Memory Cells in Response to Antigen Exposure.. Blood, 2008, 112, 1531-1531.	0.6	0
95	Targeting Lewis Y-Positive Multiple Myeloma and Acute Myeloid Leukemia with Gene-Modified T Cells Demonstrating Memory Phenotype. Blood, 2008, 112, 3900-3900.	0.6	7
96	Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.. Blood, 2007, 110, 1167-1167.	0.6	9
97	Effects of the Tumor Microenvironment on the Efficacy of Tumor Immunotherapy. Immunological Investigations, 2006, 35, 359-394.	1.0	15
98	A DNA prime-oral Listeria boost vaccine in rhesus macaques induces a SIV-specific CD8 T cell mucosal response characterized by high levels of Î±4Î²7 integrin and an effector memory phenotype. Virology, 2006, 354, 299-315.	1.1	24
99	Tumor sensitivity to IFN-? is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors. Cancer Immunology, Immunotherapy, 2005, 54, 477-488.	2.0	31
100	Lymphocyte-facilitated tumour cell adhesion to endothelial cells: the role of high affinity leucocyte integrins. Pathology, 2003, 35, 50-55.	0.3	5
101	Detection of anti-phosphatidylethanolamine antibodies using flow cytometry. Cytometry, 1999, 36, 46-51.	1.8	13